Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$994.10M
EBITDA Margin
-31.64%
TTM Avg
-36.17%
3Y Avg
-63.38%
5Y Avg
-163.90%
Market Cap
$1.01B
EBITDA Margin
-358.45%
TTM Avg
-358.45%
3Y Avg
-358.45%
5Y Avg
-358.45%
Market Cap
$1.01B
EBITDA Margin
-351.42%
TTM Avg
-184.18%
3Y Avg
-130.50%
5Y Avg
-161.84%
Market Cap
$985.37M
EBITDA Margin
-114.71%
TTM Avg
-284.80%
3Y Avg
-531.58%
5Y Avg
-445.59%
Market Cap
$979.88M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
EBITDA Margin
-0.59%
TTM Avg
3.42%
3Y Avg
-15.99%
5Y Avg
-18.77%
Market Cap
$1.02B
EBITDA Margin
-1556.38%
TTM Avg
-1235.25%
3Y Avg
-1029.62%
5Y Avg
-1004.15%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vor Biopharma Inc. (VOR) | $998.37M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $994.10M | -31.64% | -36.17% | -63.38% | -163.90% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | -358.45% | -358.45% | -358.45% | -358.45% |
| Immatics N.V. (IMTX)vs › | $1.01B | -351.42% | -184.18% | -130.50% | -161.84% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $988.62M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $985.37M | -114.71% | -284.80% | -531.58% | -445.59% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $979.88M | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | -0.59% | 3.42% | -15.99% | -18.77% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | -1556.38% | -1235.25% | -1029.62% | -1004.15% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 8.03% | 9.94% | 10.00% | 10.00% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
